• An AXL decoy receptor with enhanced GAS binding properties

  2024-02-22

  

  An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer Kinase Inhibitor Library and a murine breast cancer cell line in grafting

• Receptor tyrosine kinase Axl is a member of the TAM

  2024-02-22

  

  Receptor tyrosine kinase Axl is a member of the TAM (Tyro3/Axl/Mer) family, and has reported been associated with a spectrum of human cancers [8]. Numerous studies have revealed that the oncogenic potential of Axl is attributed to the anti-apoptotic and proliferative signaling pathways triggered by

• br Dual role of autophagy in human diseases Emerging evidenc

  2024-02-22

  

  Dual role of autophagy in human diseases Emerging evidence suggests that autophagy serves as a double-edged sword in several human diseases, such as CNS diseases (Rubinsztein et al., 2015), arteriosclerosis (Schrijvers et al., 2011) and cancer (Ozpolat and Benbrook, 2015). Likewise, currently the

• br Aurora A Aurora B and Aurora C small molecule

  2024-02-22

  

  Aurora-A, Aurora-B and Aurora-C small molecule inhibitors Nicholas et al. described phenotypic cellular screening of new highly potent and selective class of Aurora kinase inhibitors. Fragment based approach was utilized; core structure of 57 (Fig. 5) was optimized and selective inhibitor 58 (Fig

• br The future of cancer therapeutics with Aurora

  2024-02-22

  

  The future of cancer therapeutics with Aurora kinase inhibitors Involvement of Aurora kinases in deregulating multiple tumor suppressor and oncogenic pathways together with the preclinical findings on the efficacy of Aurora kinase inhibitors in attenuating growth of tumor Melatonin suggests that

• br Experimental section br Competing interests br Author s c

  2024-02-22

  

  Experimental section Competing interests Author's contributions Acknowledgement This research is partially supported by a seed fund for the Center for Drug Discovery and Translational Research (LS) and a research grant by Fujifilm (VPS and LS). The Sponsors played no roles in study desig

• In the present study we showed

  2024-02-22

  

  In the present study, we showed that 15-LOX metabolites, which are the precursors of anti-inflammatory and pro-resolving lipid mediators, were decreased in the unaffected skin area of the OS model rats by comprehensive lipidomics analyses. Furthermore, subsequent microarray analyses demonstrated tha

• br Experimental EPR spectra of

  2024-02-22

  

  Experimental EPR spectra of probes 1a–f were recorded on a Bruker EMX-1572 operating at X-band (9.0–9.9 GHz), at 21 ± 1 °C. The EPR parameters were the same in all experiments: microwave power, 1 mW; modulation amplitude, 5 G; time constant, 10.24 ms; and conversion time, 40.96 ms. Reduced gluta

• br Acknowledgments The authors thank Claudia Wittrock for he

  2024-02-21

  

  Acknowledgments The authors thank Claudia Wittrock for her excellent technical assistance. The work was supported by grants of the Deutsche Forschungsgemeinschaft (SFB974 TP B05) and of the Anton-Betz-Stiftung to N.K. A.M. is an associate member of the iBrain graduate school at the University of

• Furthermore to address the concern that the observed positiv

  2024-02-21

  

  Furthermore, to address the concern that the observed positive in vitro activity results might be stymied by the propensity of such assays to display false positives due to the inherent noxiousness of the tested compounds, all analogs were evaluated against Vero cells in an MTT assay. Some of the mo

• SNOG Our results showed that oral administration

  2024-02-21

  

  Our results showed that oral administration of cordycepin, in the concentrations of 5 and 10mg/kg for 3weeks, exerted no influence on body weight and hippocampus weight in mice. Although some reports have pointed out that cordycepin had toxic effects because it may be potential for inducing cell dea

• A borderline significant effect of women s age has

  2024-02-21

  

  A borderline significant effect of women's age has been observed for ADA6 only. For ADA2 the proportion of the *1/*1 genotype is 69.4% in women aged ≤36 years vs. 66.9% in women aged ≥36 years (p=0.944). The proportion of ADA6*1 allele carriers is 32.6% in women aged ≤36 years vs. 49. 8 in women age

• Until now five muscarinic receptor M genes

  2024-02-21

  

  Until now, five muscarinic receptor (M1-5) genes have been cloned, but, M1-3 receptors are functionally recognized in the lungs. Smooth muscle contraction is mainly mediated by M3. M2 may also participate in the contraction via Gi protein which leads to a decrease in cAMP. On the other hand, M2 is l

• The next level of possible correlation and

  2024-02-21

  

  The next level of possible correlation and comparison between the α7 and 5HT3 receptors is at the subunit arrangement and protein folding. Crystal structures of the nicotinic and serotoninergic CMK receptors [45], [46] reinforced the concept of similarities between these families of receptors. Name

• The reductase activity in patients with OHD as

  2024-02-21

  

  The 5α-reductase activity in patients with 21-OHD, as assessed by the 5α-THF to 5β-THF (ratio 3) and by the 5α-17HP to 17HP (ratio 4) ratios, showed a similar pattern of activities (Fig. 2A–C) and significant correlations (ratio 1 vs. ratio 3; rs=0.67; pIn Clotrimazole to the 5α-reducase activity,

15304 records 186/1021 page Previous Next First page 上5页 186187188189190 下5页 Last page